Galderma, the Swiss dermatology company behind Cetaphil and Alastin, has agreed to buy ZO Skin Health for $1.5 billion in cash, giving the company a much larger position in physician-dispensed skincare sold through dermatologists, plastic surgeons and medical spas.The acquisition, announced October 14, 2026, would give Galderma 100% ownership of... Read More »